Stockreport

H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough” to Olema Oncology's ( OLMA ) OPERA-02 trial, which is evaluating palazes [Read more]